Bacterial Infections Clinical Trial
Official title:
The Effect of Iron Fortification of Complementary Foods on Iron Status and Infant Gut Microbiota in Kenya
| Verified date | June 2013 |
| Source | Swiss Federal Institute of Technology |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Kenya: Ethical Review Committee |
| Study type | Interventional |
Infants and children under two years are the group with the highest rates of iron deficiency
anemia. Provision of sufficient dietary iron to this age group is a challenge, and in-home
iron fortification of complementary foods using micronutrient powders can be an effective
approach. However, WHO has recently cautioned against untargeted use of in-home
micronutrient powders that contain the entire iron RDA for a child in a single dose in areas
with high rates of infections from malaria and diarrheal disease. Therefore, in this study,
we will investigate the effect on the infant gut microbiota of a low dose (ca. 25% of the
RDA) of highly bioavailable iron, provided by a micronutrient powder added to a
complementary food.
The study aim is to determine if in-home fortification using an iron-containing
micronutrient powder in Kenyan infants will improve iron status and/or modify the
composition and metabolic activity of the gut microbiota. Active surveillance will be done
weekly to monitor the health of the infants.
Our study will be done in a subgroup (n=160) of a larger double-blind controlled feeding
trial in which 330 infants will be randomized to receive a micronutrient powder containing
either 2.5 mg iron or no iron for 1 year. In our substudy, the infants will be studied only
over the first 6 months of the 1 year intervention. Blood samples, taken at baseline and
after 6 months will be used to define the iron status and the anemia level of the infants.
Stool samples (2 at baseline before intervention, 6 throughout the study and additional
samples in case of diarrhea) will be obtained for analysis of the gut microbiota. In the
entire study (n=330), we will measure changes in iron status over 1 year.
| Status | Completed |
| Enrollment | 160 |
| Est. completion date | October 2012 |
| Est. primary completion date | September 2012 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 24 Weeks to 28 Weeks |
| Eligibility |
Inclusion Criteria: - Mother at least =15 years of age, infants 5.5- 6.5 months - Willingness to provide informed consent - Apparent good health - Long-term residence in study site and anticipating residing in the area for at least 3 years - Speak a Mjikenda language or Kiswahili in the home - Willingness to provide blood samples during clinic visits Exclusion Criteria: - Hemoglobin <70 g/L for infants; these infants will be referred for treatment at the local health clinic/hospital. - Acute or chronic pulmonary, cardiovascular, hepatic, renal or neurological condition or any other finding that in the opinion of the PI or co-researchers that would increase risk of participating in the study. - Other conditions that in the opinion of the PI or co-researchers would jeopardize the safety or rights of a participant in the trial or would render the participant unable to comply with the protocol |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science
| Country | Name | City | State |
|---|---|---|---|
| Kenya | Kikoneni Clinic | Kikoneni | Kwale district |
| Lead Sponsor | Collaborator |
|---|---|
| Swiss Federal Institute of Technology | University of KwaZulu, University of Nairobi |
Kenya,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | gut microbiota composition | Changes in gut microbiota composition | Fecal sample after 2 months | Yes |
| Secondary | iron status | Efficacy of iron fortification in complementary foods | 12 months | Yes |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03726216 -
Xydalba Utilization Registry in France
|
||
| Completed |
NCT03605498 -
OR PathTrac (Tracking Intra-operative Bacterial Transmission)
|
||
| Withdrawn |
NCT05269121 -
Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections
|
Phase 1/Phase 2 | |
| Completed |
NCT02541695 -
Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli
|
N/A | |
| Recruiting |
NCT02074865 -
Children's Antibiotic Resistant Infections in Low Income Countries
|
N/A | |
| Completed |
NCT01932034 -
Prospective Study to Optimize Vancomycin Dosing in Children and Adults Using Computer Software
|
N/A | |
| Completed |
NCT01689207 -
To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI)
|
Phase 1 | |
| Completed |
NCT01412801 -
Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings
|
Phase 2 | |
| Not yet recruiting |
NCT01159470 -
The Rate of C-reactive Protein (CRP) Increase as a Marker for Bacterial Infections in Children
|
N/A | |
| Completed |
NCT00983255 -
Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)
|
Phase 1 | |
| Completed |
NCT00678106 -
Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections
|
Phase 1 | |
| Completed |
NCT00799591 -
French Study In ICU Patients Treated With Tigecycline
|
N/A | |
| Completed |
NCT01074775 -
Human Innate Immune Responses To Mycobacterial Aerodigestive Tract Infection
|
N/A | |
| Completed |
NCT00478855 -
Tazocin Intervention Study
|
Phase 4 | |
| Terminated |
NCT00431028 -
Sub-Tenon's Injection of Triamcinolone and Ciprofloxacin in a Controlled-Release System for Cataract Surgery
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT03634904 -
Serum Ceftazidime Concentrations in Hemodialysis Patients
|
N/A | |
| Recruiting |
NCT05684705 -
Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100
|
Phase 1 | |
| Recruiting |
NCT03858387 -
PK/PD and Clinial Outcomes of Beta-lactams in ICU Patients
|
||
| Enrolling by invitation |
NCT04764058 -
Efficacy and Safety of Colistin Based Antibiotic Therapy
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06319235 -
Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®
|
Phase 1/Phase 2 |